Literature DB >> 24656661

Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.

Weidong Pan1, Brian R Lahue2, Yao Ma2, Latha G Nair1, Gerald W Shipps2, Yaolin Wang1, Ronald Doll1, Stéphane L Bogen3.   

Abstract

The discovery of 3,3-disubstituted piperidine 1 as novel p53-HDM2 inhibitors prompted us to implement subsequent SAR follow up directed towards piperidine core modifications. Conformational restrictions and further functionalization of the piperidine core were investigated as a strategy to gain additional interactions with HDM2. Substitutions at positions 4, 5 and 6 of the piperidine ring were explored. Although some substitutions were tolerated, no significant improvement in potency was observed compared to 1. Incorporation of an allyl side chain at position 2 provided a drastic improvement in binding potency.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; HDM2; Protein–protein interaction; p53

Mesh:

Substances:

Year:  2014        PMID: 24656661     DOI: 10.1016/j.bmcl.2014.02.055

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  5 in total

1.  Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.

Authors:  Stéphane L Bogen; Weidong Pan; Craig R Gibeau; Brian R Lahue; Yao Ma; Latha G Nair; Elise Seigel; Gerald W Shipps; Yuan Tian; Yaolin Wang; Yinghui Lin; Ming Liu; Suxing Liu; Asra Mirza; Xiaoying Wang; Philip Lipari; Cynthia Seidel-Dugan; Daniel J Hicklin; W Robert Bishop; Diane Rindgen; Amin Nomeir; Winifred Prosise; Paul Reichert; Giovanna Scapin; Corey Strickland; Ronald J Doll
Journal:  ACS Med Chem Lett       Date:  2016-01-20       Impact factor: 4.345

2.  Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 In Vivo.

Authors:  Rosemary Huckvale; Alice C Harnden; Kwai-Ming J Cheung; Olivier A Pierrat; Rachel Talbot; Gary M Box; Alan T Henley; Alexis K de Haven Brandon; Albert E Hallsworth; Michael D Bright; Hafize Aysin Akpinar; Daniel S J Miller; Dalia Tarantino; Sharon Gowan; Angela Hayes; Emma A Gunnell; Alfie Brennan; Owen A Davis; Louise D Johnson; Selby de Klerk; Craig McAndrew; Yann-Vaï Le Bihan; Mirco Meniconi; Rosemary Burke; Vladimir Kirkin; Rob L M van Montfort; Florence I Raynaud; Olivia W Rossanese; Benjamin R Bellenie; Swen Hoelder
Journal:  J Med Chem       Date:  2022-06-02       Impact factor: 8.039

Review 3.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.

Authors:  Yujun Zhao; Angelo Aguilar; Denzil Bernard; Shaomeng Wang
Journal:  J Med Chem       Date:  2014-11-14       Impact factor: 7.446

4.  Identification of Kinases Responsible for p53-Dependent Autophagy.

Authors:  Stephanie L Celano; Lisette P Yco; Matthew G Kortus; Abigail R Solitro; Hakan Gunaydin; Mark Scott; Edward Spooner; Ronan C O'Hagan; Peter Fuller; Katie R Martin; Stuart D Shumway; Jeffrey P MacKeigan
Journal:  iScience       Date:  2019-04-23

Review 5.  Chemical Variations on the p53 Reactivation Theme.

Authors:  Carlos J A Ribeiro; Cecília M P Rodrigues; Rui Moreira; Maria M M Santos
Journal:  Pharmaceuticals (Basel)       Date:  2016-05-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.